Joshua H. Bilenker, President & CEO at Loxo Oncology, Inc. (LOXO), sold 9,200 shares at $152.04 ($1.4M) on 2018-11-26, disclosed to the SEC on 2018-11-28.
Open-market sale of $1.4M LOXO by President & CEO. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $152.04 | 3,655 | $556K | 39.4% |
| 2 | $152.75 | 1,995 | $305K | 21.6% |
| 3 | $154.07 | 676 | $104K | 7.4% |
| 4 | $155.08 | 2,210 | $343K | 24.3% |
| 5 | $156.20 | 664 | $104K | 7.4% |
| Total | $153.37 avg | 9,200 |
| $1.4M |
| 100% |
| Filing → |
| LOXO | SELL | 2018-12-12 | $2.7M | — | Filing → |
| LOXO | SELL | 2018-12-12 | $1.0M | — | Filing → |
| LOXO | SELL | 2018-11-28 | $1.2M | — | Filing → |